Background: Drug-drug interplay (DDI) is a critical public well being challenge. The L1000 database of the LINCS undertaking has collected hundreds of thousands of genome-wide expressions induced by 20,000 small molecular compounds on 72 cell traces. Whether or not this unified and complete transcriptome information useful resource can be utilized to construct a greater DDI prediction mannequin continues to be unclear. Due to this fact, we developed and validated a novel deep studying mannequin for predicting DDI utilizing 89,970 recognized DDIs extracted from the DrugBank database (model 5.1.4).
Outcomes: The proposed mannequin consists of a graph convolutional autoencoder community (GCAN) for embedding drug-induced transcriptome information from the L1000 database of the LINCS undertaking; and an extended short-term reminiscence (LSTM) for DDI prediction. Comparative analysis of varied machine studying strategies demonstrated the superior efficiency of our proposed mannequin for DDI prediction. Lots of our predicted DDIs have been revealed within the newest DrugBank database (model 5.1.7). Within the case research, we predicted medication interacting with sulfonylureas to trigger hypoglycemia and medicines interacting with metformin to trigger lactic acidosis, and confirmed each to induce results on the proteins concerned within the metabolic mechanism in vivo.
Conclusions: The proposed deep studying mannequin can speed up the invention of recent DDIs. It could actually help future medical analysis for safer and simpler drug co-prescription.

Type I Diabetes Serum, Human Donor |
|||
MBS170481-1Sample | MyBiosource | 1Sample | EUR 310 |
Type I Diabetes Serum, Human Donor |
|||
MBS170481-5Samples | MyBiosource | 5Samples | EUR 960 |
Type I Diabetes Serum, Human Donor |
|||
MBS170481-5x5Samples | MyBiosource | 5x5Samples | EUR 4110 |
Plasma - Type I Diabetes - Patient Sample |
|||
MBS170490-1Sample | MyBiosource | 1Sample | EUR 310 |
Plasma - Type I Diabetes - Patient Sample |
|||
MBS170490-5Samples | MyBiosource | 5Samples | EUR 1005 |
Plasma - Type I Diabetes - Patient Sample |
|||
MBS170490-5x5Samples | MyBiosource | 5x5Samples | EUR 4310 |
Human Muscle Myoblasts, Diabetes Type I |
|||
ABC-TC3956 | AcceGen | 1 vial | Ask for price |
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
Single Donor Human Type I Diabetes Urine |
|||
IRHUURESDIBTI250ML | Innovative research | each | EUR 1063 |
Description: Single Donor Human Type I Diabetes Urine |
Single Donor Human Type I Diabetes Urine |
|||
IRHUURESDIBTI50ML | Innovative research | each | EUR 439 |
Description: Single Donor Human Type I Diabetes Urine |
Single Donor Human Type I Diabetes Urine |
|||
MBS8421330-250mL | MyBiosource | 250mL | EUR 1285 |
Single Donor Human Type I Diabetes Urine |
|||
MBS8421330-50mL | MyBiosource | 50mL | EUR 595 |
Single Donor Human Type I Diabetes Urine |
|||
MBS8421330-5x250mL | MyBiosource | 5x250mL | EUR 5540 |
Whole Blood - Type I Diabetes - Patient Sample |
|||
MBS170486-1Sample | MyBiosource | 1Sample | EUR 310 |
Whole Blood - Type I Diabetes - Patient Sample |
|||
MBS170486-5x1Sample | MyBiosource | 5x1Sample | EUR 4310 |
Preadipocytes, visc 1M cells, Diabetes Type I |
|||
LOPT-5023 | Westburg | each | EUR 1155.54 |
Preadipocytes, subcu 1M cells, Diabetes Type I |
|||
LOPT-5021 | Westburg | each | EUR 782.64 |
Diabetes (Type 1) Exosome |
|||
P141-DB1 | 101Bio | - | Ask for price |
Diabetes (Type 2) Exosome |
|||
P141-DB2 | 101Bio | - | Ask for price |
Human Type 2 Diabetes PB |
|||
ABC-TC4312 | AcceGen | 1 pack | Ask for price |
Description: Non-RI dependent diabetes, or Type 2 Diabetes, is characterized by hyperglycemia that is caused by a combination of RI resistance and the body's inability to compensate by producing more RI. |
Human Type 1 Diabetes Leukopak |
|||
ABC-TC4310 | AcceGen | 1 pack | Ask for price |
Description: RI dependent diabetes, or Type 1 Diabetes is caused by the pancreas producing little to no RI. |
Human Type 2 Diabetes Leukopak |
|||
ABC-TC4311 | AcceGen | 1 pack | Ask for price |
Description: Non-RI dependent diabetes, or Type 2 Diabetes, is characterized by hyperglycemia that is caused by a combination of RI resistance and the body's s inability to compensate by producing more RI. |
Human Type I Diabetes Peripheral Blood Mononuclear Cells |
|||
ABC-TC4263 | AcceGen | 1 vial | Ask for price |
Description: Peripheral blood mononuclear cells are isolated from Type I Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type I PBMCs is available upon request. |
Diabetes (Type 1) Exosome RNA |
|||
P241-DB1 | 101Bio | - | Ask for price |
Diabetes (Type 2) Exosome RNA |
|||
P241-DB2 | 101Bio | - | Ask for price |
D-Adipose-Derived stem cells, human, Type I Diabetes |
|||
LOPT-5007 | Westburg | each | EUR 748.19 |
Human Type II Diabetes PB Plasma |
|||
ABC-TC4266 | AcceGen | 1 vial | Ask for price |
Description: Type II Diabetes peripheral blood plasma is obtained by centrifugation of the Type II Diabetes PB. This product has a diminished number of cells and platelets. Fresh Diabetic Type II PB plasma is available upon request. |
Type II Diabetes Serum, Human Donor |
|||
MBS170482-1Sample | MyBiosource | 1Sample | EUR 310 |
Type II Diabetes Serum, Human Donor |
|||
MBS170482-5Samples | MyBiosource | 5Samples | EUR 960 |
Type II Diabetes Serum, Human Donor |
|||
MBS170482-5x5Samples | MyBiosource | 5x5Samples | EUR 4110 |
Plasma - Type II Diabetes - Human Patient |
|||
MBS170491-1Sample | MyBiosource | 1Sample | EUR 310 |
Plasma - Type II Diabetes - Human Patient |
|||
MBS170491-5Samples | MyBiosource | 5Samples | EUR 1005 |
Plasma - Type II Diabetes - Human Patient |
|||
MBS170491-5x5Samples | MyBiosource | 5x5Samples | EUR 4310 |
Human iPS Cell Line (Type 2 Diabetes) |
|||
CSC-00849L | Creative Bioarray | One Frozen vial | Ask for price |
D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type I |
|||
LOCC-2919 | Westburg | each | EUR 1920.94 |
Single Donor Human Type II Diabetes Urine |
|||
IRHUURESDIBTII250ML | Innovative research | each | EUR 1063 |
Description: Single Donor Human Type II Diabetes Urine |
Single Donor Human Type II Diabetes Urine |
|||
IRHUURESDIBTII50ML | Innovative research | each | EUR 439 |
Description: Single Donor Human Type II Diabetes Urine |
Single Donor Human Type II Diabetes Urine |
|||
MBS8421331-250mL | MyBiosource | 250mL | EUR 1285 |
Single Donor Human Type II Diabetes Urine |
|||
MBS8421331-50mL | MyBiosource | 50mL | EUR 595 |
Single Donor Human Type II Diabetes Urine |
|||
MBS8421331-5x250mL | MyBiosource | 5x250mL | EUR 5540 |
Human Muscle Myoblasts, Diabetes Type II |
|||
ABC-TC3957 | AcceGen | 1 vial | Ask for price |
Description: Diabetic Type I and Type II HSMM-Human Skeletal Muscle Myoblasts are isolated from donors diagnosed with either Diabetes Type I or Diabetes Type II. Additional donor information is available by contacting Scientific Support. |
Whole Blood - Type II Diabetes - Patient Sample |
|||
MBS170487-1Sample | MyBiosource | 1Sample | EUR 310 |
Whole Blood - Type II Diabetes - Patient Sample |
|||
MBS170487-5x1Sample | MyBiosource | 5x1Sample | EUR 4310 |
D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type I |
|||
LOCC-2914 | Westburg | each | EUR 1888.07 |
HighQC™ Human IPS Cell (Type 2 Diabetes) |
|||
ABC-SC0005T | AcceGen | 1 vial | Ask for price |
Description: Induced Pluriopotent Stem Cells (iPSCs) are a type of pluripotent stem cells that can be derived directly from adult somatic cells . The derived iPSCs can propagate indefinitely, as well as give rise to other cell types in the body. iPS cells, thus, hold great promise in the field of regenerative medicine by representing a single source of cells that could be used to replace those damaged/diseased cells. |
Preadipocytes, visc 1M cells, Diabetes Type II |
|||
LOPT-5024 | Westburg | each | EUR 1155.54 |
Preadipocytes, subcu 1M cells, Diabetes Type II |
|||
LOPT-5022 | Westburg | each | EUR 782.64 |
D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type I |
|||
LOCC-2917 | Westburg | each | EUR 1880.03 |
D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type I |
|||
LOCC-2927 | Westburg | each | EUR 1299.42 |
D-HCAEC – Diseased Human Coronary Artery Endothelial Cells – Diabetes Type I |
|||
LOCC-2921 | Westburg | each | EUR 1884.64 |
Human Type II Diabetes Peripheral Blood Mononuclear Cells |
|||
ABC-TC4265 | AcceGen | 1 vial | Ask for price |
Description: Human Peripheral Blood Mononuclear Cells are available as positive and negative controls for T-cell monitoring in ELISPOT, ELISA, cytokine bead array, tetramer/pentamer, and flow cytometry assays. A peripheral blood mononuclear cell is defined as any blood cell with a round nucleus. These blood cells are a critical component in the immune system to fight infection and adapt to intruders. The lymphocyte population consists of CD4+ and CD8+ T cells, B cells and Natural Killer cells, CD14+ Monocytes, and Basophils/Neutrophils/Eosinophils/Dendritic cells. These cells are often extracted from whole blood or from leukopacks using ficoll, a hydrophilic polysaccharide that separates layers of blood, with monocytes and lymphocytes forming a buffy coat under a layer of plasma.Samples from each donor are tested via PCR to confirm non-reactivity. Peripheral blood mononuclear cells are isolated from Type II Diabetes peripheral blood by diluting the whole blood with PBS and using gradient separation techniques. After centrifugation,the mononuclear cell layer is collected. Mononuclear Cells can be processed further to isolate subpopulations. Fresh Diabetic Type II PBMCs is available upon request. |
D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type I |
|||
LOCC-2923 | Westburg | each | EUR 1920.94 |
D-Adipose-Derived stem cells, human, Type II Diabetes |
|||
LOPT-5008 | Westburg | each | EUR 748.19 |
D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type I |
|||
LOCC-2915 | Westburg | each | Ask for price |
D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type I |
|||
LOCC-2929 | Westburg | each | EUR 1169.49 |
D-HAEC – Diseased Human Aortic Endothelial – Diabetes Type II |
|||
LOCC-2920 | Westburg | each | EUR 1920.94 |
HighQC™ Human IPS Cell (Episomal/ Diabetes Type II/ Adipose) |
|||
ABC-SC0011T | AcceGen | 1 vial | Ask for price |
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
D-AoSMC (Diseased Human Aortic Smooth Muscle), Diabetes Type II |
|||
LOCC-2916 | Westburg | each | Ask for price |
HighQC™ Human IPS Cell (IPSC From PBMC/ Diabetes Type II/ Episomal) |
|||
ABC-SC0009T | AcceGen | 1 vial | Ask for price |
Description: Gentaur offers human iPS cell lines derived from PBMCs, dermal fibroblasts, or adipose tissue of patients with Parkinson's Disease (PD) and Diabetes II. These iPS cells are established from a single clone and expanded in feeder-free conditions. |
D-HCAEC – Diseased Human Coronary Artery Endothelial – Diabetes Type II |
|||
LOCC-2922 | Westburg | each | EUR 1884.64 |
D-CASMC – Diseased Human Coronary Artery Smooth Muscle – Diabetes Type II |
|||
LOCC-2918 | Westburg | each | EUR 1880.03 |
HighQC™ Human IPS Cell (IPSC From Fibroblast/ Diabetes Type II/ Episomal) |
|||
ABC-SC0010T | AcceGen | 1 vial | Ask for price |
Description: Gentaur is is proud to offer human iPS cell lines derived from the human dermal fibroblasts from patients with Type 2 Diabetes (T2D). The pertinent donor information is available upon request. These iPS cells are established from a single clone and expanded in feeder-free conditions. Normal human iPS cell lines are also available as separate products . We also provide custom iPSC generation and iPSC differentiation services to meet your needs. |
D-HMVEC – Diseased Cardiac Microvascular Endothelial Cells – Diabetes Type II |
|||
LOCC-2928 | Westburg | each | Ask for price |
D-HEK-Ad – Diseased Human Adult Epidermal Keratinocytes – Diabetes Type II |
|||
LOCC-2926 | Westburg | each | EUR 841.52 |
D-HPAEC – Diseased Human Pulmonary Artery Endothelial Cells – Diabetes Type II |
|||
LOCC-2924 | Westburg | each | Ask for price |
HighQC™ Human Bone Marrow Derived Mesenchymal Stem Cell/ Type II Diabetes Patient |
|||
ABC-SC0027T | AcceGen | 1 vial | Ask for price |
Description: Human MSCs (Bone Marrow Derived) from a single adult donor clinically diagnosed with Type II Diabetes. The MSCs are compatible with our MSC Expansion Medium for Bone Marrow Derived MSCs.All of the cells provided are tested and are negative for HIV-1, HIV-2, Hepatitis B and Hepatitis C as detected by PCR. The cells are confirmed to be negative for mycoplasma and other detectable microbial contamination. |
D-PASMC (Diseased Human Pulmonary Artery Smooth Muscle Cells), Diabetes Type II |
|||
LOCC-2913 | Westburg | each | EUR 1935.75 |
Linearity FD Special Diabetes |
|||
K889M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
D-HMVEC – Diseased Human Dermal Microvascular Endothelial Cells – Diabetes Type II |
|||
LOCC-2930 | Westburg | each | Ask for price |
D-RPTEC – Diseased Human Renal Proximal Tubule Epithelial Cells – Diabetes Type II |
|||
LOCC-2925 | Westburg | each | EUR 2091.71 |
Single Donor Human Diabetes Serum |
|||
ISERSDIB | Innovative research | each | EUR 209 |
Description: Single Donor Human Diabetes Serum |
Human Diabetes Lung Tissue Lysate |
|||
IHULGDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Lung Tissue Lysate |
Human Diabetes Lung Tissue Lysate |
|||
MBS8414460-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Lung Tissue Lysate |
|||
MBS8414460-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Single Donor Human Diabetes Serum |
|||
MBS8421607-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes Ileum Tissue Lysate |
|||
IHUILMDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Ileum Tissue Lysate |
Human Diabetes Colon Tissue Lysate |
|||
IHUCLNDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Colon Tissue Lysate |
Single Donor Human Diabetes Plasma |
|||
IPLASDIB | Innovative research | each | EUR 209 |
Description: Single Donor Human Diabetes Plasma |
Human Diabetes Colon Tissue Lysate |
|||
MBS139594-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Colon Tissue Lysate |
|||
MBS139594-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Ileum Tissue Lysate |
|||
MBS8413586-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Ileum Tissue Lysate |
|||
MBS8413586-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Single Donor Human Diabetes Plasma |
|||
MBS8421060-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human Diabetes Jejunum Tissue Lysate |
|||
IHUJEJDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Jejunum Tissue Lysate |
Human Diabetes Stomach Tissue Lysate |
|||
IHUSTDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Stomach Tissue Lysate |
Human Diabetes Stomach Tissue Lysate |
|||
MBS8420033-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Stomach Tissue Lysate |
|||
MBS8420033-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Jejunum Tissue Lysate |
|||
MBS8413808-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Jejunum Tissue Lysate |
|||
MBS8413808-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Duodenum Tissue Lysate |
|||
IHUDUODIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Duodenum Tissue Lysate |
Human Diabetes Pancreas Tissue Lysate |
|||
IHUPCSDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Pancreas Tissue Lysate |
Human Diabetes Pancreas Tissue Lysate |
|||
MBS8416917-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Pancreas Tissue Lysate |
|||
MBS8416917-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Duodenum Tissue Lysate |
|||
MBS8410767-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Duodenum Tissue Lysate |
|||
MBS8410767-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes Esophagus Tissue Lysate |
|||
IHUESOPDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Esophagus Tissue Lysate |
Human Diabetes Esophagus Tissue Lysate |
|||
MBS8411234-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Esophagus Tissue Lysate |
|||
MBS8411234-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
IHUADPTVDIBTL100UG | Innovative research | each | EUR 2663 |
Description: Human Diabetes AdiposeVisceral Tissue Lysate |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
MBS136954-01mg | MyBiosource | 0.1mg | EUR 3320 |
Human Diabetes AdiposeVisceral Tissue Lysate |
|||
MBS136954-5x01mg | MyBiosource | 5x0.1mg | EUR 14765 |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
IHUSKMDIBTL100UG | Innovative research | each | EUR 1413 |
Description: Human Diabetes Skeletal Muscle Tissue Lysate |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
MBS8419496-01mg | MyBiosource | 0.1mg | EUR 1810 |
Human Diabetes Skeletal Muscle Tissue Lysate |
|||
MBS8419496-5x01mg | MyBiosource | 5x0.1mg | EUR 7965 |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
IHUADPTSDIBTL100UG | Innovative research | each | EUR 2663 |
Description: Human Diabetes AdiposeSubcutaneous Tissue Lysate |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
MBS136950-01mg | MyBiosource | 0.1mg | EUR 3320 |
Human Diabetes AdiposeSubcutaneous Tissue Lysate |
|||
MBS136950-5x01mg | MyBiosource | 5x0.1mg | EUR 14765 |
Diabetes Drug Leads Bioactive Peptide Library |
|||
L-012 | PHOENIX PEPTIDE | 160 peptides | EUR 7938 |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
IHUPCSDIBTLM100UG | Innovative research | each | EUR 1199 |
Description: Human Diabetes Pancreas Lysate Membrane Fraction |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
MBS8416918-01mg | MyBiosource | 0.1mg | EUR 1550 |
Human Diabetes Pancreas Lysate Membrane Fraction |
|||
MBS8416918-5x01mg | MyBiosource | 5x0.1mg | EUR 6780 |
Linearity FLQ Special Diabetes for Roche Systems |
|||
K929M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
Tissue, Section, Human Disease, Diabetes, Eye (Frozen) |
|||
MBS640656-5Slides | MyBiosource | 5Slides | EUR 930 |
Tissue, Section, Human Disease, Diabetes, Eye (Frozen) |
|||
MBS640656-5x5Slides | MyBiosource | 5x5Slides | EUR 3955 |
Tissue, Total Protein, Human Disease, Diabetes, Lung |
|||
MBS657041-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Lung |
|||
MBS657041-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Skin |
|||
MBS657133-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Skin |
|||
MBS657133-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Linearity FLQ Special Diabetes for Abbott Systems |
|||
K956M-5 | Audit MicroControls | 5 x 2 mL | EUR 374 |
Tissue, Section, Human Disease, Diabetes, Lung (Frozen) |
|||
MBS640535-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Lung (Frozen) |
|||
MBS640535-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Skin (Frozen) |
|||
MBS640139-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Skin (Frozen) |
|||
MBS640139-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Brain |
|||
MBS657014-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Brain |
|||
MBS657014-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Liver |
|||
MBS657060-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Liver |
|||
MBS657060-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Colon |
|||
MBS657406-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Colon |
|||
MBS657406-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Heart |
|||
MBS657486-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Heart |
|||
MBS657486-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Colon (Frozen) |
|||
MBS640835-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Colon (Frozen) |
|||
MBS640835-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Brain (Frozen) |
|||
MBS640760-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Brain (Frozen) |
|||
MBS640760-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Heart (Frozen) |
|||
MBS640578-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Heart (Frozen) |
|||
MBS640578-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Liver (Frozen) |
|||
MBS640704-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Liver (Frozen) |
|||
MBS640704-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Spleen |
|||
MBS657230-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Spleen |
|||
MBS657230-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Kidney |
|||
MBS657520-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Kidney |
|||
MBS657520-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Lung (Paraffin) |
|||
MBS640452-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Lung (Paraffin) |
|||
MBS640452-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Kidney (Frozen) |
|||
MBS639978-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Kidney (Frozen) |
|||
MBS639978-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Spleen (Frozen) |
|||
MBS640944-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Spleen (Frozen) |
|||
MBS640944-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Adrenal |
|||
MBS657074-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Adrenal |
|||
MBS657074-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Total Protein, Human Disease, Diabetes, Stomach |
|||
MBS657368-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Stomach |
|||
MBS657368-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Colon (Paraffin) |
|||
MBS640373-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Colon (Paraffin) |
|||
MBS640373-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Adrenal (Frozen) |
|||
MBS640239-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Adrenal (Frozen) |
|||
MBS640239-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Section, Human Disease, Diabetes, Liver (Paraffin) |
|||
MBS640786-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Liver (Paraffin) |
|||
MBS640786-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Stomach (Frozen) |
|||
MBS640568-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Stomach (Frozen) |
|||
MBS640568-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Pancreas |
|||
MBS657129-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Pancreas |
|||
MBS657129-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Frozen) |
|||
MBS640252-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Frozen) |
|||
MBS640252-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Tissue, Total Protein, Human Disease, Diabetes, Esophagus |
|||
MBS657305-1mg | MyBiosource | 1mg | EUR 820 |
Tissue, Total Protein, Human Disease, Diabetes, Esophagus |
|||
MBS657305-5x1mg | MyBiosource | 5x1mg | EUR 3470 |
Tissue, Section, Human Disease, Diabetes, Stomach (Paraffin) |
|||
MBS640658-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Stomach (Paraffin) |
|||
MBS640658-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Frozen) |
|||
MBS640725-5Slides | MyBiosource | 5Slides | EUR 755 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Frozen) |
|||
MBS640725-5x5Slides | MyBiosource | 5x5Slides | EUR 3170 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
IHUSKMDIBTLM100UG | Innovative research | each | EUR 1199 |
Description: Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
Tissue, Membrane Protein, Human Disease, Diabetes, Pancreas |
|||
MBS639798-01mg | MyBiosource | 0.1mg | EUR 695 |
Tissue, Membrane Protein, Human Disease, Diabetes, Pancreas |
|||
MBS639798-5x01mg | MyBiosource | 5x0.1mg | EUR 2915 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Paraffin) |
|||
MBS639953-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Pancreas (Paraffin) |
|||
MBS639953-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
MBS8419497-01mg | MyBiosource | 0.1mg | EUR 1550 |
Human Diabetes Skeletal Muscle Lysate Membrane Fraction |
|||
MBS8419497-5x01mg | MyBiosource | 5x0.1mg | EUR 6780 |
Tissue, Total Protein, Human Disease, Diabetes, Whole Eye |
|||
MBS657222-1mg | MyBiosource | 1mg | EUR 1430 |
Tissue, Total Protein, Human Disease, Diabetes, Whole Eye |
|||
MBS657222-5x1mg | MyBiosource | 5x1mg | EUR 6225 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Paraffin) |
|||
MBS640383-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Esophagus (Paraffin) |
|||
MBS640383-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Total Protein, Human Disease, Diabetes, Bone Marrow |
|||
MBS657533-1mg | MyBiosource | 1mg | EUR 1430 |
Tissue, Total Protein, Human Disease, Diabetes, Bone Marrow |
|||
MBS657533-5x1mg | MyBiosource | 5x1mg | EUR 6225 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Frozen) |
|||
MBS640718-5Slides | MyBiosource | 5Slides | EUR 930 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Frozen) |
|||
MBS640718-5x5Slides | MyBiosource | 5x5Slides | EUR 3955 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Paraffin) |
|||
MBS640435-5Slides | MyBiosource | 5Slides | EUR 510 |
Tissue, Section, Human Disease, Diabetes, Bone Marrow (Paraffin) |
|||
MBS640435-5x5Slides | MyBiosource | 5x5Slides | EUR 2145 |
Tissue, Total Protein, Human Disease, Diabetes, Skeletal Muscle |
|||
MBS657193-1mg | MyBiosource | 1mg | EUR 820 |
Background: Diabetes and consuming problems are steadily comorbid. This explicit comorbidity just isn’t solely usually poorly recognised, however is tough to deal with and has a excessive mortality.
Methodology: On this article, we’ll briefly evaluation the connection between diabetes and consuming problems. We are going to evaluation the present NICE and different steering and studies regarding each diabetes and consuming problems in the UK. We are going to then describe the suggestions of the 2018 Welsh Authorities Consuming Dysfunction Service Evaluate and the 2021 the Scottish Authorities Consuming Dysfunction Service Evaluate concerning diabetes and consuming problems, which is able to result in service change.
Conclusions: We conclude that this can be a comparatively underdeveloped however necessary space the place there must be additional service improvement and extra collaboration between diabetes and consuming dysfunction providers.
Introduction: Sodium-glucose co-transporter-2 (SGLT2) inhibitors reasonably scale back glucose ranges in type-2 diabetes mellitus (T2DM). Some instances of diabetic ketoacidosis (DKA) have been reported with SGLT2 inhibitors. Nevertheless, information on the long-term security of dapagliflozin in Saudi Arabia are missing. The current research aimed to watch the protection of dapagliflozin in sufferers with T2DM and consider the change in HbA1c through the remark interval in comparison with baseline.
Strategies: This was an area, potential, single-arm, non-interventional, regulatory post-marketing research. The research was performed in Saudi Arabia from Might 2017 to September 2019. Sufferers acquired both 5 or 10 mg dapagliflozin together with weight loss program and train modifications to deal with T2DM. The incidence of antagonistic occasions was noticed over the therapy period and for Three days after administering the final dose of dapagliflozin.
Outcomes: A complete of 527 sufferers have been recruited within the research, 524 of which have been eligible for the statistical evaluation. About 62% have been males. The median (IQR) age was 52.3 (14.8) years, whereas the median (IQR) physique mass index was 31.6 (7.7) kg/m2. The median (IQR) period because the sufferers have been first identified with T2DM was 8.78 (6.73) years. The commonest comorbidities have been hyperlipidemia (51.1%) and hypertension (41.1%). Virtually three-quarters of the research inhabitants (73.7%) acquired different antidiabetic drugs along with dapagliflozin.
Over a interval of 12 months, a complete of 106 antagonistic occasions have been skilled by 65 (12.33%) sufferers. Vulvovaginal pruritus (3.1%), dysuria (2.7%), polyuria (1.3%), urinary tract infections (1%), fatigue (0.8%), and hypoglycemia (0.8%) have been among the many reported antagonistic occasions. One case of DKA (0.2%) was reported. The imply (SD) HbA1c% degree considerably decreased from 8.6 (1.6) % at baseline to succeed in 7.2 (1.2) % after 12 months of therapy (p < 0.0001).
Conclusion: Dapagliflozin was discovered to be a effectively tolerated and efficient therapy possibility for T2DM sufferers in Saudi Arabia. Vulvovaginal pruritus and dysuria have been the commonest antagonistic occasions.
Goals: To judge the long-term penalties of espresso ingesting in sufferers with kind 2 diabetes.
Information synthesis: PubMed, Scopus, and Net of Sciences have been searched to November 2020 for potential cohort research evaluating the affiliation of espresso ingesting with danger of heart problems (CVD) and mortality in sufferers with kind 2 diabetes. Two reviewers extracted information and rated the certainty of proof utilizing GRADE method. Random-effects fashions have been used to estimate the hazard ratios (HRs) and 95% CIs. Dose-response associations have been modeled by a one-stage mixed-effects meta-analysis. Ten potential cohort research with 82,270 instances have been included. In comparison with these with no espresso consumption,
the HRs for consumption of Four cups/d have been 0.79 (95%CI: 0.72, 0.87; n = 10 research) for all-cause mortality, 0.60 (95%CI: 0.46, 0.79; n = 4) for CVD mortality, 0.68 (95%CI: 0.51, 0.91; n = 3) for coronary coronary heart illness (CHD) mortality, 0.72 (95%CI: 0.54, 0.98; n = 2) for CHD, and 0.77 (95%CI: 0.61, 0.98; n = 2) for whole CVD occasions. There was no vital affiliation for most cancers mortality and stroke. There was an inverse monotonic affiliation between espresso ingesting and all-cause and CVD mortality, and inverse linear affiliation for CHD and whole CVD occasions. The understanding of proof was graded average for all-cause mortality, and low or very low for different outcomes.
Conclusions: Consuming espresso could also be inversely related to the danger of mortality in sufferers with kind 2 diabetes. Nevertheless, extra analysis is required contemplating kind of espresso, sugar and cream added to espresso, and historical past of CVD to current extra assured outcomes.